These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8526191)

  • 1. High-dose busulfan and cyclophosphamide followed by autologous bone marrow transplantation and/or peripheral blood progenitor cell rescue for metastatic breast cancer.
    Kalaycioglu ME; Lichtin AE; Andresen SW; Tuason L; Bolwell BJ
    Am J Clin Oncol; 1995 Dec; 18(6):491-4. PubMed ID: 8526191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer.
    Demirer T; Buckner CD; Appelbaum FR; Clift R; Storb R; Myerson D; Lilleby K; Rowley S; Bensinger WI
    Bone Marrow Transplant; 1996 May; 17(5):769-74. PubMed ID: 8733696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
    Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
    Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: a role for peripheral blood progenitor transplant.
    Myers SE; Mick R; Williams SF
    Bone Marrow Transplant; 1994 Apr; 13(4):449-54. PubMed ID: 8019470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tandem autotransplantation for the treatment of metastatic breast cancer.
    Broun ER; Sridhara R; Sledge GW; Loesch D; Kneebone PH; Hanna M; Hromas R; Cornetta K; Einhorn LH
    J Clin Oncol; 1995 Aug; 13(8):2050-5. PubMed ID: 7636548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose cyclophosphamide, carboplatin, and etoposide with autologous stem cell rescue in patients with breast cancer.
    deMagalhaes-Silverman M; Rybka WB; Lembersky B; Bloom EJ; Lister J; Pincus SM; Voloshin M; Wilson J; Ball ED
    Am J Clin Oncol; 1996 Apr; 19(2):169-73. PubMed ID: 8610643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
    Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Nagasawa S
    Cancer; 1994 Mar; 73(6):1678-85. PubMed ID: 7512436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.
    Ayash LJ; Elias A; Wheeler C; Reich E; Schwartz G; Mazanet R; Tepler I; Warren D; Lynch C; Gonin R
    J Clin Oncol; 1994 Jan; 12(1):37-44. PubMed ID: 7505807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer.
    Gisselbrecht C; Extra JM; Lotz JP; Devaux Y; Janvier M; Peny AM; Guillevin L; Bremond D; Delain M; Herbrecht R; Lepage E; Maraninchi D
    Bone Marrow Transplant; 1996 Nov; 18(5):857-63. PubMed ID: 8932837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer.
    Klumpp TR; Mangan KF; Glenn LD; Macdonald JS
    Bone Marrow Transplant; 1993 Apr; 11(4):337-9. PubMed ID: 8097937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Busulfan-containing pre-transplant regimens for the treatment of solid tumors.
    Ghalie R; Reynolds J; Valentino LA; Manson S; Korenblit AD; Feingold JM; Adler SS; Pruett J; Kaizer H
    Bone Marrow Transplant; 1994 Sep; 14(3):437-42. PubMed ID: 7994269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
    Bitran JD; Samuels B; Klein L; Hanauer S; Johnson L; Martinec J; Harris E; Kempler J; White W
    Bone Marrow Transplant; 1996 Feb; 17(2):157-62. PubMed ID: 8640160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin.
    Ayash LJ; Elias A; Schwartz G; Wheeler C; Ibrahim J; Teicher BA; Reich E; Warren D; Lynch C; Richardson P; Schnipper L; Frei E; Antman K
    J Clin Oncol; 1996 Nov; 14(11):2984-92. PubMed ID: 8918496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.
    Holland HK; Dix SP; Geller RB; Devine SM; Heffner LT; Connaghan DG; Hillyer CD; Hughes LL; Miller RL; Moore MR; Winton EF; Wingard JR
    J Clin Oncol; 1996 Apr; 14(4):1156-64. PubMed ID: 8648370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer.
    Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Sniecinski I
    Cancer; 1994 Jan; 73(1):125-34. PubMed ID: 7903906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy.
    Phillips GL; Shepherd JD; Barnett MJ; Lansdorp PM; Klingemann HG; Spinelli JJ; Nevill TJ; Chan KW; Reece DE
    J Clin Oncol; 1991 Oct; 9(10):1880-8. PubMed ID: 1919638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of recurrent and refractory pediatric solid tumors with high-dose busulfan and cyclophosphamide followed by autologous bone marrow rescue.
    Graham ML; Yeager AM; Leventhal BG; Wiley JM; Civin CI; Strauss LC; Hurwitz CA; Dubowy RL; Wharam MD; Colombani PM
    J Clin Oncol; 1992 Dec; 10(12):1857-64. PubMed ID: 1453200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation.
    Ghalie R; Richman CM; Adler SS; Cobleigh MA; Korenblit AD; Manson SD; McLeod BC; Taylor SG; Valentino LA; Wolter J
    J Clin Oncol; 1994 Feb; 12(2):342-6. PubMed ID: 8113841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose chemotherapy with autologous bone marrow support as consolidation after standard-dose adjuvant therapy in primary breast cancer patients with seven or more involved axillary lymph nodes.
    Lalisang RI; Hupperets PS; ten Haaft MA; Jansen RL; Schouten HC
    Bone Marrow Transplant; 1998 Feb; 21(3):243-7. PubMed ID: 9489646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.